23 Jan Can Going to Rehab Lead To Losing Your Job?
Posted at 12:21h
in Addiction
Entering rehab to combat addiction is akin to embarking on a heroic quest. However, it is a journey fraught with challenges and many people have the ever-present fear of losing one's job looming like a relentless adversary.
The Perilous Precipice
The decision to confront addiction through addiction treatment is a courageous step, yet it can also be perilous. The shadow of job loss casts a long and foreboding silhouette over this undertaking. The stigma surrounding addiction and the lack of understanding from some employers can ignite a fear that burns fiercely in the hearts of those seeking help.
Dr. Di Ciano[/caption]
Patricia Di Ciano, PhD
Prof. Durazzo[/caption]
Timothy C. Durazzo, PhD
Clinical Neuropsychologist and Research Scientist
Mental Illness Research and Education Clinical Centers
VA Palo Alto Health Care System
Professor, Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
MedicalResearch.com: What is the background for this study?
-There are a limited number of studies investigating changes in human brain structure, in individuals with an alcohol use disorder, with longer term abstinence after treatment.
-Our study was the first to assess for change in cortical thickness over approximately 7 months of abstinence in those seeking treatment of alcohol use disorder.
-Cortical thickness in humans is genetically and phenotypically distinct from other brain structural measures such as cortical volume and surface area.
-Therefore, assessment of changes in cortical thickness with longer-term abstinence provides additional information on how human brain structure recovers with sobriety.
Leana Pande[/caption]
MedicalResearch.com Interview with:
Leana Pande
Touro College of Osteopathic Medicine
MedicalResearch.com: What is the background for this study?
Response: Buprenorphine is not a new drug. It was developed in the 1960s with the intent of providing the benefits of opioids, without the addictive side effects. Unlike many prescription opioids,1 use of this Schedule III drug is increasing.2 It is often characterized as a partial agonist at the mu-opioid receptor (Figure-Right). Buprenorphine is available in many routes of administration and also with (brand name Suboxone) or without naloxone. Buprenorphine is a first-line pharmacotherapy for pregnant women with OUD.3 This review was completed in order for the benefits, and risks, of buprenorphine to be more fully appreciated and inform utilization for both opioid use disorder (OUD) and the treatment of pain.
Lotfi Khemiri
Centre for Psychiatry Research
Stockholm, Sweden
MedicalResearch.com: What is the background for this study?
Response: Our study used large-scale national register data in close to 2 million children, and found that parental abuse of both alcohol and drugs are associated with increased risk of intellectual disability in the offspring. Importantly, the risk increase was observed in both mothers and fathers which to the best of our knowledge is a novel finding, and may be explained by both genetic and environmental factors including toxic effects of substance intake on fetal development.
Luke Cavanah[/caption]
Luke Cavanah, BS
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: It is well-known that schedule II stimulants, which are those that are highly addictive and include amphetamine, methylphenidate, and lisdexamfetamine, have had increasing use and misuse in the US.
Despite understanding the presence of this phenomenon, the reason for it is poorly understood. The purpose of this study was to see if rising rates of schedule II stimulants are related to the legalization of medical marijuana. We were interested in this because schedule II stimulants are primarily used as the treatment for attention-deficit hyperactivity disorder (ADHD), chronic cannabis use has been demonstrated to cause neurocognitive deficits resembling that of ADHD, and the conditions have been shown to affect similar brain regions.
Dr. Kruger[/caption]
Jessica Kruger PhD
Clinical Associate Professor of Community Health and Health Behavior
University at Buffalo School of Public Health and Health Professions
MedicalResearch.com: What is the background for this study?
Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products.
The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT.
Dr. Potnuru[/caption]
Paul Potnuru, MD
Assistant Professor
Anesthesiology, Critical Care and Pain Medicine
The John P. and Kathrine G. McGovern Medical School
The University of Texas Health Science Center at Houston
Dr. Miller[/caption]
Alex P. Miller, PhD
TranSTAR T32 Postdoctoral Fellow
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO
MedicalResearch.com: What is the background for this study?
Response: Adolescent cannabis use is increasing in the United States. Prior research suggests that people who start using cannabis earlier are more likely to engage in problematic use and also experience greater mental health challenges and socioeconomic disadvantages overall. For example, children who begin using cannabis early are more likely to have behavioral problems and disorders and are more less likely to complete school.
In our study, we used data from the Adolescent Brain Cognitive Development (ABCD) Study, which is following nearly 12,000 kids across the nation to track behavior and brain development as well as health from middle childhood to young adulthood. We looked at what factors are associated with the initiation of cannabis use by age 12-14.
Dr. Lovestead[/caption]
Tara M Lovestead, PhD, (She/her/hers)
Dr. D'Orsogna[/caption]
Maria-Rita D'Orsogna Ph.D.
Professor, Mathematics
California State University, Northridge
Adjunct Associate Professor
Department of Computational Medicine at UCLA
MedicalResearch.com: What is the background for this study?
Response: Drug overdose deaths have been increasing in the USA for the past two decades. A ‘third wave’ of overdose fatalities started in 2013, with a shift from prescription opioids towards synthetic ones, in particular illicit fentanyl.
To examine trends in drug overdose deaths by gender, race and geography in the United States during the period 2013-2020, we used an epidemiological database provided by the Centers for Disease Control and Prevention, extracting rates by race and gender in all 50 states plus the District of Columbia. We considered the impact of four main drug categories psychostimulants with addiction potential such as methamphetamines; heroin; prescription opioids and synthetic opioids such as fentanyl and its derivatives.
Dr. Lazarus[/caption]
Philip Lazarus, PhD
Boeing Distinguished Professor, Pharmaceutical Sciences
Professor, Dept of Pharmaceutical Sciences
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA 99210
MedicalResearch.com: What is the background for this study?
Response: Smoking and tobacco use remains a major health issue. Smokers use cigarette over the course of the day because the levels of nicotine, the addictive agent in cigarettes and other forms of tobacco, dimmish with time in the bloodstream due to the breakdown of nicotine by enzymes in the body. By inhibiting the breakdown of nicotine in smokers, one would expect that the levels of nicotine would remain higher after smoking a single cigarette, and that these individuals may not require lighting up another cigarette so quickly, reducing the number of cigarettes smoked over the course of a day. This could have a profound effect on reducing the overall harm incurred from smoking or from using other forms of tobacco.
In a single previous study, smokers who used a CBD inhaler exhibited a 40% reduction in cigarette use. In addition, while cannabis users are often smokers, previous studies have indicated that they smoke less cigarettes than non-cannabis-using cigarette smokers. In previous studies published in 2021, we found that major cannabinoids present in cannabis like THC and CBD inhibit major metabolizing enzymes in our body, including several that are important in drug metabolism. We hypothesized that CBD and its major active metabolite, 7-hydroxy (OH)-CBD, may also be inhibiting one or more of the enzymes important in the metabolism (or breakdown) of nicotine.
Alcoholism is a serious problem that affects people of all ages, genders, and backgrounds. It is defined as an addiction to alcohol, in which the person feels unable to control their drinking and continues to drink despite its negative consequences. Alcoholism can lead to health problems, family issues, financial difficulties, and even death
Alcoholism is a chronic, progressive disease that is characterized by a strong craving for alcohol, difficulty controlling one's drinking, and continued drinking despite negative consequences. People with alcoholism often have trouble holding down a job, maintaining relationships, and taking care of their health. If you or someone you know is struggling with alcoholism, it's important to get help as soon as possible. There are many resources available to help people recover from this disease.
Alden Mileto, BA
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: The drug buprenorphine is a partial opioid agonist, originally developed in the 1960s as an alternative to the stronger full opioid mu receptor agonists like morphine. Today, the drug is sometimes used for pain, but is more often used as a treatment for Opioid Use Disorder (OUD). Since the 2002 federal approval for buprenorphine use in treatment of OUD, there has been an increase in buprenorphine prescription across all states.
However recent studies have showed a disproportionate increase in buprenorphine prescriptions to rural/ less populated areas in comparison to urban/densely populated areas. The objective of this study [1] was to analyze the trends in buprenorphine distribution, overall and by three-digit zip codes, in Pennsylvania from 2010-2020.
